Nov 30, 2022 / 01:00PM GMT
Christopher Joseph Raymond - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Let's go ahead and get started. Thanks, everybody, for attending day 2 of the 34th Annual Piper Sandler Healthcare Conference. My name is Chris Raymond. I'm 1 of the biotech analysts here at Piper. It's my pleasure to introduce our first company for the day, Regeneron Pharmaceuticals. Joining us to my left is Bob Landry, the CFO; and to his left is Ryan Crowe, the Vice President of IR.
So as was the case yesterday and through the conference, this is a fireside chat format, so meant to be very informal. So if anybody has any questions in the audience, just I'll be looking out for your raised hand, and I'll make sure your question gets asked and answered. So before I jump into my questions, I think Ryan might have a few safe harbor comments and then Bob will give a 2- or 3-minute overview of sort of level of setting where Regeneron is today, and then we'll jump into Q&A. So take it away, guys.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Regeneron Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers